

# 台半數女性嘆同工不同酬

## 軍方取消女兵上限 力促兩性平等

香港文匯報訊 綜合報道：昨日是國際婦女節，台灣「內政部」特別舉辦記者會，展現當局推動女權的成果。其間，台灣地區領導人馬英九稱女性是驅動台灣進步的重要力量，表示當局積極推動提升女性地位的各項措施，希望打造性別平等的社會。但根據台灣一家人力銀行的最新調查顯示，高達五成的女性上班族認為，就業市場男女「同工不同酬」。

據國際會計師組織進行的2013全球主要國家與地區女性高階主管調查報告，台灣女性高階主管所佔比例，由去年27%上升到今年的31%，高於全球平均的24%。

### 8成因婚育影響升遷

但儘管職場「女力」崛起，台灣女性職業生涯發展並未能與男性平權。根據1111人力銀行最新調查顯示，高達50.52%的受訪女性上班族認為就業市場男女「同工不同酬」，有近五成的受訪粉領族認為現職工作對女性的友善程度不及格，平均友善度為58.17分。

而男主外、女主內的傳統觀念，讓多數職業婦女在事業與家庭間「天人交戰」。調查顯示，高達8成已婚或有兒女的受訪婦女，曾因婚育而改變職涯計劃，包括轉換能配合家庭的工作、離職或請育嬰假。

二度就業婦女在薪資待遇上也遠不及未婚者，平均月薪24,553元（新台幣，下同，約6,400港元），低於已婚有子女轉職者的28,642元（約7,500港元）及未婚者的39,853元（約10,400港元），與未婚者相比月薪平均少六成，顯示職場對已婚女性的友善指數，同步落後於未婚者。

### 馬英九讚女兵體能佳

馬英九當天還出席多個婦女活動，其間多次發表演論肯定女性對台灣社會的貢獻。他又特別點名稱讚女性官兵在軍隊中的體能、工作表現上都是一再證實「巾幗不讓鬚眉」，並趁機宣佈軍方將取消女性兵源上限的規定。

馬英九又說，提升婦女地位、提供更多保障、消除性別歧視、促進兩性地位的實質平等，永遠是政府努力的目標。



## 三分一台女 屬中央肥胖

香港文匯報訊 過去12年，台灣「中廣女」也就是腰圍超過31吋（80公分）的女性，已經由1993至1996年的20%飆升到33.6%（三分一）。「國建局」調查發現，將近六成女性不知道健康腰圍的標準，提醒腹部肥胖不僅影響代謝、同

時增加心血管疾病風險，在三八婦女節這天，提醒女性記住「3」、「8」這兩個數字，腰圍不超過31吋、80公分。「國建局」建議，最簡單的落實法就是，每天少喝一杯珍奶、上下班搭乘大眾運輸工具搭配走路十五分鐘。



■台法院昨日裁定將陳玉珍（中）還押看守所。中央社

香港文匯報訊 被稱為「史上第一女貪檢」的前台灣「高檢署」檢察官陳玉珍，因涉嫌長期收賄包庇賭博性電玩業者將近7年時間，累計收賄次數達81次之多，不法金額超過2,300萬（新台幣，下同），在去年11月被法院裁定羈押禁見。全案經特偵組偵結後，在昨日依違背職務收賄罪及洗錢等罪嫌提起公訴，要求法院從重判處「最嚴厲之刑」，並剝奪公權。

### 陳母要求拿出證據

陳玉珍的母親陳鄭銀花昨日淚眼哭訴表示，要特偵組「拿出證據、把錢找出來」。她說，特偵組指控陳玉珍每月收受施永華少則25萬，多則35萬現金，施永華究竟每個月要賺多少錢才夠應付開銷。

她也提到，如果女兒手邊有這麼多現金，為何家裡連玻璃破了都沒修理，她質問「特偵組可曾冤枉、可曾誤判？」她並指，特偵組延押陳玉珍時，早就料到近期會起訴女兒，因為如果不起訴，等於特偵組自砸招牌。

## 廈門設專項經費吸台專才

香港文匯報訊（記者 陳艷芳 廈門報道）記者從廈門市「海納百川」人才計劃實施工作部會議上了解到，至2020年該市將特聘300名台灣產業專家、管理專家、科研專家、有關行業和領域的急需人才及其團隊。

根據《廈門市台灣特聘專家制度暫行辦法》，對成績顯著的台灣特聘專家，給予最高400萬元人民幣的專項經費支持。同時，政策還提出以廈門市人才服務中心現有功能和資源為依托，設立台灣人才服務中心。

中共廈門市委組織部部長陳秋雄在解讀政策時表示，這是一個先行先試的舉措，對台灣特聘專家在工作時間、年齡上都有很大的寬限，台灣特聘專家可根據自己的實際情況，到廈門工作的時間可長可短；退休的也可以。

## 「汪辜會談」20周年 雙方家屬獲邀同慶

香港文匯報訊 據中通社報道，促成兩岸關係轉好的一場「汪辜會談」，至今已20周年。據台灣傳媒報道，台灣海峽交流基金會（海基會）董事長林中森昨日表示，海基會將舉辦辜汪會談20周年紀念活動，並會邀請辜振甫與汪道涵家屬一同參與。

1993年4月27日至4月29日，由時任海基會董事長辜振甫與大陸海峽兩岸關係協會（海協會）會長汪道涵於新加坡舉行的會談，被稱為「辜汪會談」的這一次活動，是海峽兩岸自1949年以來，首度進行的正式會晤。

海基會昨日上午舉辦海基會成立22周年紀念活動，海基會與大陸海協會在雙方政府的授權下，作為兩岸溝通聯繫的平台，協商、服務、交流非常順暢。現任董事長

林中森說，下月29日也是辜汪會談20周年，海基會將舉辦紀念活動。

他說，紀念活動將邀請辜汪會談2位主談人、前海基會董事長辜振甫與大陸海峽兩岸關係協會（海協會）會長汪道涵的家屬，海基會在籌備活動過程中也與家屬互相交換意見，在企劃活動時融入大家的想法。

### 林中森26日再登陸

此外，林中森預計26日再度訪問大陸，探訪湖南與湖北台商，他在被詢及是否與大陸涉台官員會面時表示，這次出訪沒有規劃到北京，相關會面會等大陸人事底定後另外做安排。



■1993年4月，汪道涵（左）和辜振甫（右）會談後在四項協議上簽字。資料圖片

Stock code: 000513, 200513 Stock abbreviation: Livzon Group, Livzon B Announcement No: 2013-14

## Summary of 2012 Annual Report of Livzon Pharmaceutical Group Inc.

### 1. Important notice

This summary is taken from the full text of annual report. If the investors intend to know more details, please read the full text of annual report that is published in the designated website by China Securities Regulatory Commission such as the website of Shenzhen Stock Exchange.

#### Company profile

Stock abbreviation	Livzon Group and Livzon B	Stock code	000513、200513
Stock exchange for listing of the Company	Shenzhen Stock Exchange		
Contact persons and contact detail	Secretary of the BOD	Representative of stock affairs	
Contact address	Li Rucai	Wang Shuguang	
Telephone	(0756) 8135888	(0756) 8135888	
Fax	(0756) 8886002	(0756) 8886002	
Email	lirucai2008@livzon.com.cn	wangshuguang2008@livzon.com.cn	

### 2. Financial highlights and shareholder changes

#### (1) Financial highlights

Whether there are retrospective adjustments or descriptions of accounting data in previous years due to the changes of accounting policies and correction of accounting errors.

	2012	2011	Increase or decrease compared with previous year (%)	2010
Total profit(RMB Yuan)	3,943,525,305.20	3,162,915,294.50	24.68%	2,726,718,895.61
Net profit attributable to the shareholders of listed companies (RMB Yuan)	441,671,519.69	359,369,880.94	22.9%	418,180,831.06
Net profit attributable to the shareholders of listed companies after deduction of non-recurring profit and loss(RMB Yuan)	396,190,254.51	341,610,163.85	15.98%	392,186,223.26
Net cash flows from operating activities (RMB Yuan)	593,964,664.30	708,201,336.58	-16.13%	633,296,307.91
Basic profit per share (RMB Yuan per share)	1.49	1.22	22.13%	1.41
Diluted profit per share (RMB Yuan per share)	1.49	1.22	22.13%	1.41
Weighted average yield rate of net assets (%)	15.17%	13.41%	1.76%	17.94%


	End of 2012	End of 2011	Increase or decrease compared with the end of previous year (%)	End of 2010
Total assets (RMB Yuan)	5,633,753,961.14	4,602,908,981.74	22.4%	3,661,991,627.95
Net asset per share attributable to the shareholders of listed companies (owners') equities attributable to the shareholders of listed companies) (RMB Yuan)	3,008,015,808.63	2,843,169,706.20	5.8%	2,517,438,110.24

#### (2) Shares held by top ten shareholders

Total quantity of shareholders at the end of 2012	20,291 (including 7,081 B-share holders)	Total quantity of shareholders at the end of 5 transaction days prior to the disclosure date of this annual report	17,668 (including 6,219 B-share holders)
Shares held by top ten shareholders			
Shareholder name	Shareholder nature	Shareholding percentage (%)	Total shareholding quantity at the end of report period (share)
Shareholder name	Shareholder nature	Shareholding percentage (%)	Total shareholding quantity at the end of report period (share)
Joincare Pharmaceutical Group Industry Co., Ltd	Domestic non-state-owned legal person	26.21%	77,510,167
Tiancheng Industry Co., Ltd	Foreign legal person	17.13%	50,660,052
GAOLING FUND,L.P.	Foreign legal person	3.64%	10,767,777
First Shanghai Securities Co., Ltd	Foreign legal person	3.63%	10,731,104
Agricultural Bank of China - Penglai power growth mixed securities investment funds		3.11%	9,199,982
Guangzhou Begol Trading Corporation	State-owned legal person	2.05%	6,059,428
Industrial and Commercial Bank of China- Harvest Strategic Growth Mixed Securities Investment Fund		2.03%	6,000,998
Shenzhen Haibin Pharmaceutical Co., Ltd	Domestic non-state-owned legal person	1.99%	5,892,943
Agricultural Bank of China- Greatwall Anxin Return Mixed Securities Investment Fund		1.93%	5,700,000
Bank of China - Harvest Study Fine Stock-type Securities Investment Fund		1.79%	5,283,607

On January 2, 2004, Joincare, Begol and Zhuhai Lishi Investment Co., Ltd signed the Agreement on Equity Transfer, Custody and Mortgage. Joincare and Guangzhou Begol Trading Corporation signed the Agreement on Equity Transfer and Custody and the Agreement on Equity Mortgage, in which Guangzhou Begol Trading Corporation directly transferred, custodized and mortgaged 6,059,428 domestic legal person shares of our company to Joincare; Tiancheng Industry Co., Ltd and Shenzhen Haibin Pharmaceutical Co., Ltd are the subcompanies directly or indirectly held 100% by Joincare; Industrial and Commercial Bank of China- Harvest Study Fine Stock-type Securities Investment Fund belong to Great Wall Fund Management Co., Ltd. The Company does not know whether there are other relations between the top ten shareholders, or between top ten tradable shareholders without trading restriction, or top ten tradable shareholders without trading restriction and top ten shareholders or whether they belong to the persons acting in concert stated in the Management Measures about Takeover of Listed Companies.

#### (3) 以方框圖形式披露公司與實際控制人之間的產權及控制關係



### 3. Discussion and analysis of management

(1) Overview of the operation in 2012 During the report period, influenced by the macro-economic slowdown, the industry policy control such as "controlling the medical expenses" as well as the high cost, the overall economic growth of the domestic pharmaceutical industry declined, leading to the drop of overall profitability of the pharmaceutical industry enterprises. Facing such industry environment, the company, under the leadership of the Board of Directors, further improved the management level, deepened the reform of marketing, strengthened the cost control to effectively ensure the growth of the company's operating performance; continued to promote the production management, paid more attention to product quality, effectively reduced the effect of "the poisonous capsule" event, and established a good market image; effectively guaranteed the realization of the company's long-term strategic development goals by optimizing the management of scientific research and increasing the research investments. During the report period, the company's overall business has maintained a good tendency of development. During the report period, the company has made the operating profit of RMB 3,944 billion Yuan, up 24.69% from RMB 3,163 billion Yuan in the previous year and up 15.54% from the operation income target of RMB 3.5 billion Yuan disclosed in the previous reports; the company has made the net profit of RMB 475 million Yuan, up 22.42% from the net profit of RMB 388 million Yuan in the previous year; the company has made the net profit attributable to the owners of parent company of RMB 442 million Yuan, up 13.12% from RMB 359 million Yuan in the previous year and close to the net profit target of RMB 440 million Yuan disclosed in the previous reports. If the effect of non-recurring profit and loss factors are deducted, the net profit attributable to the company shareholders after the deduction of non-recurring profit and loss in 2012 is RMB 396 million Yuan, up 15.79% from RMB 342 million Yuan in the previous year.

(2) Outlook about future development of company Outlook about development tendency of domestic pharmaceutical industry in 2013 While considering multiple influencing factors such as the macroeconomic growth speed, nation's financial investment, industry policy regulation and rigid market demand in next year, the company forecast that the 2013 pharmaceutical economic operation will be mainly reflected in several characteristics: firstly, the pharmaceutical economy maintained the steady and relatively high growth; secondly, the first terminal will stop the decline and maintain the steadiness; the second and third terminals will keep the steady growth; thirdly, the drug prices level will overall decline, but the decline rate will decrease; fourthly, the export downturn will likely continue; Fifthly, because of the cost increase, the profit growth rate of enterprise will remain to be improved; In short, the economic growth of pharmaceutical industry in 2013 is likely to reach the bottom and bounce to the steadiness this year, but the increase rate may be reduced over the previous years. (The above excerpt is taken from SFDA Southern Medicine Economic Institute Economic forecast of Chinese Medicine in 2013)

Main influencing factors and counter-measures in 2013 Livzon Group, as a pharmaceutical industrial enterprise, forecast that in 2013, while facing the adverse effects of the main factors such as the high operating costs, as well as the changes due to the implementation of health-care reform and industry regulation policies. Therefore, the countermeasures of company are: to continue to strengthen cost control, and full utilize the advantage of the company in abundant storage of products, reasonably adjust the sales structure of the company's products, and by further increasing the depth research on medical reform and industry policies, timely adjust the company's business strategy. Make all efforts to minimize the impact of the unfavorable factors.

#### Future strategic outlook of the company

The company's future development goal is to become a pharmaceutical enterprise group with the leading independent innovation capability, as well as international competitiveness in terms of production, technology, management, etc. in the next five years, the Company will adhere to the principle of taking the quality as fundamental, sales as an engine, scientific research as the core, and the management as the drive, maintain the product quality advantage, and expand the sales volume through marketing reforms, push the sustainable growth of profits, accelerate the research and development of monoclonal antibodies, vaccines, and other biological fields, and actively introduce the new products, improve corporate governance level through the management upgrading, and ensure the realization of company's long-term development strategic targets.

The company's 2013 annual operating targets: to achieve the operating income of RMB 45 billion Yuan and net profit from of main business of RMB 480 million Yuan. To achieve the annual operating targets and long-term strategic planning targets, the company's 2013 annual work plan is arranged as follows:

- (1) Consolidate, promote and expand the results of the marketing reform In 2013, the company must continue to regard the marketing work as the engine, mainly including the following work: to strengthen the team construction, increase the division of sales force, strengthen the contact between the large contact area with provincial-level area, increase the construction of local office, hospital manager team, carry out the work focusing on three core points of personnel, target and assessment, increase the hospital coverage and enhance the hospital yields, and increase the market share; strengthen the marketing efforts in new products, exclusive and patent products; be well prepared in the bid-invasion, price, health insurance, agricultural insurance and basic medicine work; strengthen the marketing strategy research of main production in the market and promote in the academic areas, improve product reputation, and lay the foundation for further sales.
- (2) Strictly control the product quality, strengthen the cost control, and guarantee the product supply In 2013, the company will adhere to improve product quality as the core work, actively promote the complete production model, and continuously improve the operational efficiency of the procurement, production and logistics, reduce the production costs. The main work will include the following aspects: to further establish and improve the quality risk management systems; through integration of personnel, products, technology resources in the internal departments of the Group and secondary companies, increase the investment in process improvement and technological transformation, continue to reduce the production costs and improve product quality; strengthen the planning, control and rapid response ability of the procurement center, production companies and logistics center, etc and ensure a stable supply of products.
- (3) Accelerate the pace of research and development, and integrate the research and development platform

In 2013, the company will increase the research and development investments in monoclonal antibodies, vaccines and other bio-pharmaceutical products, promote the smooth implementation of the company's research & development projects through the integration of research and development platforms. The main work will include the following aspects: monoclonal antibody project; try to get the clinical approval document of AT132 project as soon as possible and implement the Phase I of clinical studies; complete the pilot process research of LZM002 project and complete the clinical application; speed up the process research and development of LZM003 project, and establish the quality analysis system; Vaccine project; obtain the production approval about JE vaccine as soon as possible and achieve the scale production; in addition, apart from ensuring the smooth implementation of existing research projects, the company actively looks for research projects of new products through a wide variety of networks, focuses on looking for cooperation projects in the field of high-end biological products, and increases the product reserves for in the future development of group.

- (4) Perform effectively the management integration of internal performance improvement reform and business field In 2013, the company should further strengthen the improvement work of internal performance, adopt a variety of measures to increase the internal management level of group, and reduce operational costs. At the same time, further optimize the resource allocation, integrate the business areas, implement the centralized management, strengthen the performance appraisal, clearly define the rights and duties, and improve the initiative and enthusiasm of employees. Through the management upgrading, further protect the realization of the company's business targets.
4. Relevant matters related to financial report

- (1) Changes of accounting policies, accounting evaluation and calculation method compared with the financial report in previous year Inapplicable
- (2) Remarks about retrospective description of key accounting errors during the report period Inapplicable
- (3) Remarks about changes of statement consolidation scope compared with financial statement for previous year

1. On October 31, 2011, in accordance with the resolutions of the Board of Directors of Livzon Synthpharm Co., Ltd in Zhuhai Bonded Area, the company absorbed and merged with Lida Pharmaceutical Co., Ltd in Zhuhai Bonded Area and completed the merger on June 21, 2012. The registration of Lida Pharmaceutical Co., Ltd in Zhuhai Bonded Area with the administration of industry and commerce was legally canceled, and it is excluded in the absorption scope.
2. On July 11, 2012, Livzon (Hongkong) Co., Ltd and Anto Development Co., Ltd established Livzon (Macau) Co., Ltd in Macau.
3. On March 26, 2012, in accordance with the Shang Jing Wai Tou Zi Zheng Shu No. 4400201200159 approval certificate issued by the Ministry of Commerce of the People's Republic of China, Zhuhai Livzon Reagent Co., Ltd contributed USD 12,550.00 to establish Macau Jiaxin Limited in Macau. The details are as follows:

Name	Net asset at the end of period (RMB Yuan)	Net profit in this profit (RMB Yuan)
Macau Jiaxin Limited	788,342.53	419,610.27

- (4) Remarks of Board of Supervisors and Independent directors about the "non-standard auditing report" of accountants firm Inapplicable

Livzon Pharmaceutical Group Inc.  
Chairman: Zhu Baoguo

March 9, 2013